Potrero Medical wins FDA breakthrough nod for algorithm that predicts acute kidney injury
13 Sep 2022
Hayward, California-based Potrero designed its algorithm for the advanced prediction of acute kidney injury (AKI) associated with intra-abdominal hypertension (IAH) in cardiac post-surgical intensive care patients.
The company developed the Accuryn system that uses urinary catheters as diagnostic tools. The device provides real-time measurements of intra-abdominal pressure, urine output and core body temperature. It can be integrated into hospital EMR systems.
“We celebrate the breakthrough designation, and we are excited about what this will mean for patients, providers and health systems in the future,” Potrero CEO Joe Urban said in a news release. “Continuous urine output and intra-abdominal pressure are new patient parameters that, until Accuryn, have not been available to leverage as critical data streams. Combining Accuryn technology with a predictive AKI algorithm will enhance the clinical decision support we provide at the bedside.”
The company closed a $26.6 million Series C funding round in July 2018 to help support the commercialization of Accuryn. It went on to raise nearly $5.5 million in equity in October 2019.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.